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Abstract
Information regarding the processes leading to death in patients with invasive aspergillosis
(IA) is lacking. We sought to determine the causes of death in these patients, the role that IA
played in the cause, and the timing of death. The factors associated with IA-related mortality
are also analyzed. We conducted a multicenter study (2008-2011) of cases of proven and
probable IA. The causes of death and whether mortality was judged to be IA-related or IA-
unrelated were determined by consensus using a six-member review panel. A multivariate
analysis was performed to determine risk factors for IA-related death. Of 152 patients with
IA, 92 (60.5%) died. Mortality was judged to be IA-related in 62 cases and IA-unrelated in
30. The most common cause of IA-related death was respiratory failure (50/62 patients),
caused primarily by Aspergillus infection, although also by concomitant infections or severe
comorbidities. Progression of underlying disease and bacteremic shock were the most fre-
quent causes of IA-unrelated death. IA-related mortality accounted for 98% and 87% of
deaths within the first 14 and 21 days, respectively. Liver disease (HR 4.54; 95% CI, 1.69-
12.23) was independently associated with IA-related mortality, whereas voriconazole treat-
ment was associated with reduced risk of death (HR 0.43; 95% CI, 0.20-0.93). In conclu-
sion, better management of lung injury after IA diagnosis is the main challenge for
physicians to improve IA outcomes. There are significant differences in causes and timing
between IA-related and IA–unrelated mortality and these should be considered in future re-
search to assess the quality of IA care.
Introduction
Invasive aspergillosis (IA) is a leading cause of infection-related death in immunocompromised
patients [1–4]. Recent data suggest that the outcomes of this infection appear to be improving
compared with observations in the 1990s, this being due to advances in diagnosis and the intro-
duction of new antifungal agents [5–8].
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However, knowledge regarding the cause of death in patients with IA remains scarce for a
number of reasons. First, patients with IA are complex hosts with severe underlying diseases,
aggressive treatments, coexisting infections, and/or treatment complications. Second, studies
focusing specifically on the processes leading to death in these patients are lacking. Third, a
multidisciplinary approach involving a large number of physicians is common in the manage-
ment of these patients, and the final cause of death reported on the death certificate may de-
pend on the experience of the signing physician. And fourth, there is no clear consensus about
how to define the cause of a patient’s death or the role that IA may have played in this event.
This knowledge gap limits our understanding of optimal treatment strategies. It is not clear,
therefore, whether IA-related mortality is caused by factors that could be modifiable through
medical intervention.
Previous studies of IA prognosis have focused mainly on overall mortality, and they have as-
sessed risk factors for all-cause mortality [7]. Moreover, definitions of IA-related mortality are
vague [5, 6, 8]. A further aspect requiring elucidation is whether causes of death and factors as-
sociated with mortality within the first few days differ from those associated with mortality
occurring later.
The present study sought 1) to identify the immediate causes of death in a contemporary co-
hort of hospitalized patients with IA, 2) to determine the role that IA played in the cause of
death, and 3) to analyze the timing of death and risk factors associated with IA-related mortali-
ty in this cohort of patients.
Materials and Methods
Setting, patients, and study design
We conducted a retrospective multicenter study of all adults diagnosed with IA between 1 Jan-
uary 2008 and 31 December 2011 at three tertiary teaching hospitals in Barcelona, Spain. Pa-
tients who developed IA were identified by review of clinical records, of microbiology and
pathology records, and of the diagnostic codes recorded on hospital discharge. The following
information was carefully collected from medical records: demographic characteristics, under-
lying disease, use of immunosuppressive treatment, neutropenia, clinical features, diagnostic
tools, infecting Aspergillus species, antifungal and adjunctive treatment, and outcomes. In-
formed consent was waived by the Clinical Research Ethics Committee because no intervention
was involved and no patient identifying information was included. The study was approved by
the Ethical Committee of the Hospital Universitari de Bellvitge.
Definitions
We included only patients with proven and probable IA according to the definitions published
by the European Organization for Research and Treatment of Cancer/National Institute of Al-
lergy and Infectious Diseases Mycosis Study Group (EORTC/MSG) [9]. Neutropenia was de-
fined as an absolute neutrophil count of<500/mm3. Disseminated IA was defined as evidence
of infection in at least two noncontiguous sites or isolated CNS infection. The day of IA diagno-
sis was the day on which the first positive test was performed. For patients whose diagnosis was
obtained from postmortem examination, the day of death was considered to be the day
of diagnosis.
Assessment of mortality and the cause of death
Mortality was assessed at 90 days from day of diagnosis (overall mortality). Cause of death and
the role of IA in causing death were reviewed by members of clinical review panel. This panel
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was composed by 6 investigators. Data from each study’s patient were independently reviewed
by three of these investigators. Results were based on full consensus among the investigators.
The investigators were blind to the patient’s day of death. Five members of the clinical review
panel were infectious disease specialists and one was an advanced fellow in infectious diseases.
All reviewers had extensive clinical experience dealing with patients with IA. The reviewers
were asked to assign the immediate causes of death based on World Health Organization crite-
ria [10], and to assess the role that IA played in the patient’s death.
The immediate cause of death was defined as the disease process, injury, or complication
immediately preceding death. IA was considered the cause of death when the immediate cause
of death was due to this infection. IA was judged to have played a major role if death would not
have occurred had the patient not had IA, even though another condition was present that also
contributed to death. IA was defined as playing a minor role if IA was not essential in explain-
ing the patient’s death but did play some role in the event. Mortality was classified as IA-related
if IA was the cause of death or if it played a major role in the patient’s death. Mortality was de-
fined as IA-unrelated if IA played a minor role or had no role in the patient’s death.
Statistical analysis
Categorical variables were described using counts and percentages. Continuous variables were
expressed as the mean and standard deviation or median and interquartile range, depending
on the result of the Kolmogorov-Smirnov test. To detect significant differences between causes
of IA-related and IA-unrelated death we used the chi-square or Fisher’s exact test for categori-
cal variables and the Student’s t test or Mann-Whitney U test for continuous variables, as ap-
propriate. A multivariate analysis to determine independent risk factors for IA-related
mortality was performed comparing patients with IA-related death versus all other patients.
Variables shown to be significant in the univariate analysis and which were considered clinical-
ly important were entered into the multivariate analysis. The relative risks were expressed as
hazard ratios (HR) and 95% confidence intervals (CI).
The results were analyzed using SPSS version 15.0 (SPSS Inc., Chicago, IL, USA). Statistical
significance was set at α = 0.05. All reported p values are two-tailed.
Results
Study population and causes of death
A total of 152 patients with IA were enrolled in the study. Table 1 summarizes the characteris-
tics of patients hospitalized for IA, as well as their clinical features, diagnosis, and treatment.
Overall mortality (90 days) was 60.5% (92 of 152 patients). The median time to death after di-
agnosis was 16 days (IQR 6.25–33.5). The immediate causes of death are detailed in Table 2.
Mortality was judged to be IA-related in 62 cases (67.4% of deaths; 40.8% of patients). Of
these, IA was the cause of death in 36 cases (39.1% of deaths; 23.7% of patients) and was judged
to have played a major role in the patient’s death in the remaining 26 cases (28.3% of deaths;
17.1% of patients). Mortality was defined as IA-unrelated in 30 cases (32.6% of deaths; 19.7%
of patients): IA played a minor role in 18 cases (19.5% of deaths; 11.8% of patients) and had no
role in the patient’s death in 12 cases (13.0% of deaths; 7.9% of patients).
Table 2 shows the differences in cause of death between patients with IA-related versus IA-
unrelated mortality. The most common cause of IA-related death was respiratory failure (50 of
62 patients; 80.6%), caused primarily by Aspergillus infection, although also by concomitant in-
fections or severe lung comorbidities. Progression of underlying disease and septic shock
caused by bloodstream infection were the most frequent causes of IA-unrelated death.
Death in Patients with Aspergillosis
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Fifteen patients were diagnosed after death. Autopsyprovided the diagnosis of five patients
in whom the diagnostic tests to rule out IA were not performed during hospitalization. Positive
cultures and/or galactomannan results reported after death, plus necropsy results, allowed a di-
agnosis to be made in a further five patients, while positive cultures and/or galactomannan re-
sults reported after death enabled the remaining five patients to be diagnosed. Disseminated IA
was documented in 6 of these 15 patients (40%). IA was judged to have been the cause or to
have played a major role in the patient’s death in all 15 of these cases.
Timing of IA-related and IA-unrelated mortality
Survival plots and frequency distributions of death by time for IA-related and IA-unrelated
mortality are shown in Fig. 1. There were significantly different patterns in time to death for
Table 1. Patient baseline characteristics, clinical features, diagnosis, and treatment.
Characteristics Patients n = 152 %
Age, median years (IQR) 60 (49–67) -
Male sex 93 61.2
Underlying disease
Hematologic malignancy 67 44.1
Solid organ transplant 34 22.4
Hematopoietic stem cell transplant 13 8.6
Solid tumor 13 8.6
AIDS 9 5.9
Immunodeﬁciency disorder 5 3.3
Other& 12 7.8
Immunologic risk#
Neutropenia 49 32.2
Corticosteroid therapy 89 58.6
Any immunosuppressive therapy 99 65.1
Infection site
Pulmonary only 136 89.5
Disseminated IA 16 10.5
Diagnosis#
Culture$ 113 74.3
Galactomannan 95 62.5
Biopsy or autopsy 34 22.4
Type of IA
Proven 38 25.0
Probable 114 75.0
Primary antifungal therapy*
Voriconazole monotherapy 61 40.1
Voriconazole-containing regimen 92 60.5
Amphotericin B monotherapy@ 19 16.8
Combination therapy 25 16.4
& Contains patients with severe immunosuppressive treatment, mainly high dose of corticosteroids.
# Patients could have >1 characteristics within a category.
$A. fumigatus, 87 cases (76.9%); A. niger, 6 (5.3%); A. terreus, 6 (5.3%); A. ﬂavus, 12 (10.6%) other, 6 (5.3%).
* Systemic antifungal therapy with anti-Aspergillus activity given for at least 5 consecutive days.
@ Liposomal amphotericin B 13 (11.5%); Lipidic amphotericin B 6 (5.3%).
doi:10.1371/journal.pone.0120370.t001
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patients with IA-related versus IA-unrelated mortality. Median survival days for patients with
IA-related death was 10 (IQR 1.5–18.25), as compared with 43.5 (IQR 18.75–60.25) for patients
with IA-unrelated death (p<.001).
IA-related mortality accounted for 97.6% of deaths within the first 14 days and 86.7% of
deaths within the first 21 days. IA-unrelated mortality accounted for 58% of deaths from day
14 to day 90 and 68.6% of deaths from day 21 to day 90 (p<.001 for both comparisons). Of the
IA-related deaths, 66.1% occurred within 14 days, and 83.9% within 21 days. No IA-related
death was documented after 60 days of follow-up. The odds of an IA-related death occurring
Table 2. Immediate cause of death for patients with IA.
Cause of death1 IA-related death
N = 62 (%)
IA-unrelated death
N = 30 (%)
Total N = 92
(%)
p2
Respiratory failure 50 (80.6) 9 (30) 59 (64.1) <.001
- caused primarily by Aspergillus infection 24 (38.7) 0 24 (26.1) <.001
- caused by Aspergillus infection and
concomitant lung infections3
14 (22.6) 6 (20) 20 (21.7) .99
- caused by Aspergillus infection and severe
comorbidities4
12 (19.4) 3 (10) 15 (16.3) .37
Underlying disease5 6 (9.7) 12 (40) 18 (19.6) <.01
Septic shock caused by
bloodstream infection6
5 (8.1) 11 (36.7) 14 (15.2) <.01
Pulmonary hemorrhage7 10 (16.1) 0 10 (10.9) .03
Neurological conditions8 7 (11.3) 1 (3.3) 8 (8.7) .27
Multiorganic failure9 7 (11.3) 0 7 (7.6) .09
Other10 2 (3.2) 12 (40) 14 (15.2) <.001
1 More than >1 cause of death was considered in 38 patients.
2 Differences between IA-related and IA-related mortality.
3 Cytomegalovirus, 7 patients; Pseudomonas aeruginosa, 5 patients; Pneumocystis jirovecii, 3 patients; Inﬂuenza A(H1N1)pdm09, 3 patients;
Streptococcus pneumoniae, 2 patients; nocardiosis, 2 patients; Rhodococcus equi, 1 patient; respiratory syncytial virus, 1 patient; aspiration pneumonia,
1 patient. Three respiratory co-pathogens were found in 5 patients.
4 Severe chronic obstructive pulmonary disease, 8 patients; GVHD, 3 patients; and in 1 patient each: cerebrovascular disease, lung cancer, pulmonary
ﬁbrosis, and acute pulmonary thromboembolism.
5 Acute myeloid leukemia relapse, 6 patients; graft failure in organ solid recipients, 4 patients (two lung, one kidney, one liver); GVHD, 4 patients with allo-
hematopoietic stem cell transplantation; cavum massive hemorrhage secondary to solid cancer, 1 patient; advanced lung cancer, 1 patient; intestinal
obstruction in patient with metastatic cancer, 1 patient; severe aplasia after chemotherapy in one patient with chronic lymphocytic leukemia.
6 Gram-negative bacilli, 6 patients; Enterococcus spp., 4 patients; Listeria monocytogenes, 1 patient; Streptococcus pneumoniae, 1 patient; Candida
albicans, 1 patient; polymicrobial bacteremia with Enterococcus faecim and Achromobacter dentriﬁcans, 1 patient.
7 Necrotizing pneumonia caused by Aspergillus in patients with severe pancytopenia due to hematologic disease, 5 patients (in one case co-infection with
Pseudomonas aeruginosa was found); necrotizing pneumonia caused by Aspergillus in patients with pancytopenia and/or coagulopathy due to liver
disease, 3 patients; necrotizing pneumonia caused by Aspergillus, 1 case; necrotizing pneumonia caused by Aspergillus and Pseudomonas aeruginosa,
1 case.
8 Brain herniation caused by focal lesion +/- cerebral hemorrhage caused by Aspergillus in central nervous system, 5 patients; cerebral ischemic event, 2
patients; primary brain hemorrhage, 1 patient.
9 Disseminated invasive aspergillosis with multiorganic failure, 3 cases; multiorganic failure caused by respiratory failure due to Aspergillus and liver failure
due to severe underlying liver disease, 3 patients; multiorganic failure caused by respiratory failure due to Aspergillus and heart failure after cardiac
transplantation, 1 patient.
10 Clostridium difﬁcile infection, 4 patients (co-infection with CMV was found in 1 case); sudden cardiopulmonary arrest in patients with multifactorial
encephalopathy, 2 patients; sudden cardiac arrest, 2 patients; acute myocardial ischemia, 1 patient; neutropenic colitis, 1 patient, intestinal ischemia and
secondary peritonitis, 1 case; post-surgical esophageal perforation and secondary mediastinitis, 1 case; severe cachexia (adult/32 kg), 1 case; diabetic
ketoacidosis, 1 case.
doi:10.1371/journal.pone.0120370.t002
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within 14 and 21 days of presentation were 19.84-fold and 3.15-fold higher than that of an IA-
unrelated death, respectively.
Factors associated with IA-related mortality
Table 3 shows the independent factors associated with IA-related mortality. After adjustment,
chronic liver disease (HR 4.542; 95% CI, 1.69–12.23) was the only factor independently associ-
ated with IA-related mortality. Conversely, receipt of voriconazole was independently associat-
ed with reduced risk of IA-related death (HR 0.43; 95% CI, 0.20–0.93).
Fig 1. Frequency plot of IA-related and IA-unrelated mortality.
doi:10.1371/journal.pone.0120370.g001
Table 3. Independent risk factors for IA-related death.
Variable Adjusted
HR (95% CI) p
Patient-related factors
Chronic liver disease 4.54 (1.69–12.22) .003
Severe impairment on PFT1 2.46 (0.90–6.77) .081
Hematologic disease 0.99 (0.42–2.35) .992
Corticosteroid treatment 1.37 (0.61–3.06) .449
IA-related factors
Disseminated IA 2.12 (0.58–7.69) .253
Proven IA 2.23 (0.90–5.56) .986
Voriconazole treatment2 0.04 (0.20–0.93) .032
1Severe pulmonary function test abnormality.
2 Voriconazole received for at least 5 days.
doi:10.1371/journal.pone.0120370.t003
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Discussion
This multicenter study describes contemporary causes of death for adults with IA. Our cohort
is representative of patients with IA and has similar patient characteristics, clinical presenta-
tion, and antifungal therapy to those reported by the PATH Alliance [11], the largest recent
prospective description of IA patients. Previous information regarding the processes leading to
death in adults with IA is scarce. In the present study, overall mortality for patients with IA at
90 days was 60.5%. This mortality rate is high, probably due to the heterogeneous population.
IA in non-neutropenic, non-cancer patients still has a very poor prognosis, contrasting to the
increasingly better survival in hematologic patients, likely due to strategies of early diagnosis al-
lowing early appropriate treatment. Our mortality rate finding concurs with that of other in-
vestigators who reported rates ranging from 35.6% to 66% [5–8, 12]. Recently, Marr et al. [13]
reported a mortality rate at 6-weeks close to 30% in patients who had an underlying hemato-
logic malignance or hematopoietic cell trasplantation diagnosed with possible, probable, or
proven IA. Mortality was judged to be IA-related in 62 of 152 cases (40.8%), accounting for
67.4% of deaths; in the remaining 32.6% of cases death was due to IA-unrelated causes. These
data are difficult to compare with those obtained by other researchers, owing to differences in
definitions and study populations. Importantly, we found substantial differences in causes and
timing for IA-related and IA-unrelated mortality.
In our study the most frequent cause of IA-related death was respiratory failure. This was
mostly a direct result of Aspergillus infection, although there were also cases of respiratory fail-
ure in patients with coexisting infections or severe comorbidities. Pulmonary hemorrhage was
another frequent cause of IA-related death. These findings suggest the need for measures to im-
prove the care of pulmonary function in the early management of IA. It is important to note,
however, that IA is not a homogeneous disease. Its pathogenesis differs depending on the
host’s immune status [14–17], and the lung injury could occur through different pathways.
Early rollout and treatment of coinfections, as well as optimized management of chronic pul-
monary diseases, would also seem mandatory.
In our study the progression of underlying disease and septic shock caused by bacteremia
were the most frequent causes of IA-unrelated death. The prognosis of patients beyond 21 days
of IA diagnosis could be greatly influenced by improving the treatment of underlying diseases
and/or preventing and managing bacterial infections.
Although our cohort of patients was recruited at a time of improved diagnostic tests such as
chest CT and the galactomannan antigenemia assay, some cases of IA were still only diagnosed
at autopsy or post-mortem. In line with previous reports [5] these patients were more likely to
have disseminated disease. These results show that more prompt diagnosis of IA remains a
challenge for physicians.
Most of the IA-related deaths (83.9%) occurred within the first 21 days after diagnosis. In
fact, IA-related mortality accounted for 97.6% of deaths within the first 14 days. After this peri-
od the number of IA-related deaths diminished rapidly, with no IA-related death being docu-
mented after 60 days. By contrast, IA-unrelated mortality accounted for 68.6% of deaths from
day 21 to day 90 after IA diagnosis. These results suggest that assessment of survival at 12
weeks after diagnosis (a criterion used by many researchers) [5, 6, 12] is an imprecise indicator
of the efficacy of IA treatment. This finding concurs with that of other investigators [18]. Given
that the 12-week period includes a large number of deaths due to competing causes that are not
related to fungal infections, researchers interested in assessing treatment response in IA infec-
tion should therefore focus only on IA-related deaths. We believe that our study used clear and
uniform definitions that were intended to be reproducible in future studies. Studies not using
an independent clinical expert review committee to determine the cause of death for patients
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should apply a cut-off of 14 days so as to provide relevant information only about deaths di-
rectly caused by IA. Twenty-one days (3 weeks) seems to be a good cut-off for a global evalua-
tion of IA-related mortality. However, our data are retrospective and subject to limitations.
Further prospective studies to assess the optimal cutt-off point to evaluate treatment response
in IA infection should be conducted.
We found that the presence of liver disease was independently associated with an increased
risk for IA-related mortality. The association between hepatic impairment and increased risk
for mortality in patients with IA has been previously documented in hematopoietic cell trans-
plant recipients [5].Importantly, we found that voriconazole treatment was independently as-
sociated with reduced risk of IA-related death. The better mortality outcomes of patients
treated with voriconazole compared with amphotericin B therapy for IA has been demonstrat-
ed in observational studies [5, 6] and in a randomized trial [12]. Our study has several limita-
tions. One potential weakness is that the validity of using a clinical review committee to
determine the cause of death for patients with IA has not been previously established. Never-
theless, this method was chosen because it was the most practical in nature and is likely to pro-
vide more reliable data than would death certificates, most of which are signed by inexpert
practitioners with limited experience in the management of these complicated patients. Similar
clinical consensus methods have been used to classify mortality for many other conditions
[19,20]. It is nonetheless difficult to avoid subjective points of view when establishing causes of
death in these patients. We sought to address this by using precise definitions of IA-related and
unrelated mortality that were applied in a uniform manner. Researchers were blind to the tim-
ing of mortality when determining the cause of death, and all decisions were agreed by consen-
sus. A final limitation to consider is that an autopsy could not be performed for all the patients
who died.
In conclusion, this study describes the immediate causes of death in a current cohort of pa-
tients with IA. The findings suggest that better management of lung injury within the first 21
days after IA diagnosis is the main challenge for physicians in terms of improving IA outcomes.
Importantly, there were significant differences in causes and timing between IA-related and
IA-unrelated mortality and these should be considered in future research in order to assess the
quality of IA care.
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